Bumper Offer - Urjas oil Just @ Rs. 1
Azro 500 Tablet (3) is a prescription medicine that is available as a Tablet. It is primarily used for the treatment of Ear Infection, Tonsillitis, Pneumonia. Other than this, Azro 500 Tablet (3) has some other therapeutic uses, which have been discussed ahead.
The optimal dosage of Azro 500 Tablet (3) is largely dependent on the individual's body weight, medical history, gender and age. Individual symptoms and route of administration also determines the right dosage. Detailed information has been provided in the dosage section.
The most common side effects of Azro 500 Tablet (3) are Nausea or vomiting, Diarrhoea, Headache. Besides the aforementioned side effects, there are other adverse effects of Azro 500 Tablet (3) as well, which are listed below. Normally, these side effects of Azro 500 Tablet (3) are not long lasting and go away when the treatment is finished. Please speak with your doctor if these side effects worsen or persist for a longer duration.
Furthermore, you should know that effect of Azro 500 Tablet (3) is Safe for pregnant women and Safe for women who are breastfeeding. Warnings related to Azro 500 Tablet (3)'s effects on the liver, heart and kidney, if any, have been listed below.
Other contraindications of Azro 500 Tablet (3) have been discussed in the sections ahead.
Drug reaction of Azro 500 Tablet (3) with other medicines has been reported. See below for a complete list.
In addition to these precautions, you may also note that Azro 500 Tablet (3) is safe while driving, and is is addictive in nature.
Azro 500 Tablet (3) is used to treat the following -
Main Benefits
Other Benefits
This is the usual dosage recommended in most common treatment cases. Please remember that every patient and their case is different, so the dosage can be different based on the disease, route of administration, patient's age and medical history.
Find the right dosage based on disease and age
| Age Group | Dosage |
| Adult |
|
| Geriatric |
|
| 13 - 18 years (Adolescent) |
|
| 2 - 12 years (Child) |
|
| Adult(Female) |
|
| Adult(Male) |
|
Based on research, the following side effects have been observed when Azro 500 Tablet (3) is used -
Severe
Moderate
Mild
Common
Is the use of Azro 500 Tablet (3) safe for pregnant women?
Azro is safe to take during pregnancy.
Is the use of Azro 500 Tablet (3) safe during breastfeeding?
Azro is completely safe for breastfeeding women.
What is the effect of Azro 500 Tablet (3) on the Kidneys?
Azro rarely affects the kidneys.
What is the effect of Azro 500 Tablet (3) on the Liver?
Side effects of Azro rarely affect the liver.
What is the effect of Azro 500 Tablet (3) on the Heart?
Azro may have mild side effects on the heart. Most people will never see any effect on the heart.
Azro 500 Tablet (3) should not be taken with following medicines due to severe side effects it may cause to patients -
Life Threatening
Severe
Moderate
If you are suffering from any of the following diseases, you should not take Azro 500 Tablet (3) unless your doctor advises you to do so -
Is this Azro 500 Tablet (3) habit forming or addictive?
Azro 500 Tablet (3) is not addictive in nature.
Is it safe to drive or operate heavy machinery when consuming?
Yes, you can operate a vehicle or heavy machinery after taking Azro 500 Tablet (3) since it does not cause drowsiness.
Is it safe?
Yes, but take Azro 500 Tablet (3) only as per medical advice.
Is it able to treat mental disorders?
No, the use of Azro 500 Tablet (3) in mental disorders is not effective.
Interaction between Food and Azro 500 Tablet (3)
Taking Azro 500 Tablet (3) with food is safe.
Interaction between Alcohol and Azro 500 Tablet (3)
It is difficult to say anything about the effect of Azro 500 Tablet (3) and alcohol. No research has been done on this yet.
This medicine data has been created by -
References
US Food and Drug Administration (FDA) [Internet]. Maryland. USA; Package leaflet information for the user; Zithromax (azithromycin)
KD Tripathi. [link]. Seventh Edition. New Delhi, India: Jaypee Brothers Medical Publishers; 2013: Page No 754
